耐火性甲状腺功能低下症:在治疗巨细胞动脉炎期间的意外结果
Elise Deprince1, Solange Grunenwald1, Celine Mouly1
1Department of Endocrinology, Metabolic Diseases and Nutrition, Cardiovascular and Metabolic Unit Larrey University Hospital Toulouse France.
Clinical case reports
|October 24, 2025
概括
耐药性甲状腺功能低下症是口服levothyroxine治疗患者的常见挑战. 这种情况需要仔细的诊断和管理,以达到正常的甲状腺刺激激素 (TSH) 水平.
科学领域:
- 内分泌学 在内分泌学.
- 内部医学 内部医学
背景情况:
- 耐药性甲状腺功能低下症是接受口服levothyroxine的患者经常出现的临床问题.
- 它给医疗保健提供者带来了诊断和治疗方面的挑战.
研究的目的:
- 讨论耐火性甲状腺功能低下症的诊断和管理策略.
- 在受影响的患者中概述恢复正常TSH度的方法.
主要方法:
- 关于耐火性甲状腺功能低下症的文献综述.
- 对诊断标准和治疗选择的分析.
- 案例研究审查 (如果适用 - 不在摘要中指定).
主要成果:
- 耐火性甲状腺功能低下症需要进行彻底的生理病理学评估.
- 可能需要优化levothyroxine的剂量和配方.
- 必须评估对治疗的坚持和潜在的药物相互作用.
结论:
- 耐火性甲状腺功能低下症的有效管理需要个性化的方法.
- 达到正常的TSH水平对于患者的福祉至关重要.
- 进一步的研究可能会澄清最佳的长期治疗策略.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Rheumatic Heart Disease I: Introduction
426
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
426
Desensitization and Tachyphylaxis
3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K


